MétaCan
Menu
Back to cohort
Record W4408869829 · doi:10.1016/j.ajhg.2025.02.017

Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments

2025· review· en· W4408869829 on OpenAlexafffund
David Cheerie, Margaret Meserve, Danique Beijer, Charu Kaiwar, Logan Newton, Ana Lisa Taylor Tavares, Aubrie Soucy, Emma Sherrill, Stefanie Leonard, Stephan Sanders, Emily J. Blake, Nour Elkhateeb, Aastha Gandhi, Nicole Si Yan Liang, J. Morgan, Anna Verwillow, Jan Verheijen, Andrew C. Giles, Sean Williams, Maya Chopra, Laura V. Croft, Hormos Salimi Dafsari, Alice E. Davidson, Jennifer Friedman, Anne Gregor, Bushra Haque, Rosan Lechner, Kylie Montgomery, Mina Ryten, Emil Schober, Gabriele Siegel, Patricia J. Sullivan, Ella F. Whittle, Bianca Zardetto, Timothy W. Yu, Matthis Synofzik, Annemieke Aartsma‐Rus, Gregory Costain, Marlen C. Lauffer

Bibliographic record

VenueThe American Journal of Human Genetics · 2025
Typereview
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicGenomics and Rare Diseases
Canadian institutionsHospital for Sick ChildrenUniversity of TorontoSickKids Foundation
FundersMedical Research CouncilCanadian Institutes of Health ResearchGemeinnützige Hertie-StiftungMedical Research Council CanadaZonMwDeutsche ForschungsgemeinschaftHealth Data Research UKEuropean CommissionHospital for Sick ChildrenAlexander von Humboldt-Stiftung
KeywordsOligonucleotideComputational biologyDNAGeneticsBiology

Abstract

fetched live from OpenAlex

Of the around 7,000 known rare diseases worldwide, disease-modifying treatments are available for fewer than 5%, leaving millions of individuals without specialized therapeutic strategies. In recent years, antisense oligonucleotides (ASOs) have shown promise as individualized genetic interventions for rare genetic diseases. However, there is currently no consensus on which disease-causing DNA variants are suitable candidates for this type of genetic therapy. The patient identification working group of the N=1 Collaborative (N1C), alongside an international group of volunteer assessors, has developed and piloted consensus guidelines for assessing the eligibility of pathogenic DNA variants for ASO treatments. We herein present the N1C VARIANT (variant assessments toward eligibility for antisense oligonucleotide treatment) guidelines, including the guiding scientific principles and our approach to consensus building. Pathogenic, disease-causing variants can be assessed for the three currently best-established ASO treatment approaches: splice correction, exon skipping, and downregulation of RNA transcripts. A genetic variant is classified as "eligible," "likely eligible," "unlikely eligible," or "not eligible" in relation to the different approaches or as "unable to assess." We also review key considerations related to assessing the upregulation of transcripts from the wild-type allele, an emerging ASO therapeutic strategy. We provide additional tools and training materials to enable clinicians and researchers to use these guidelines for their eligibility assessments. With this initial edition of our N1C VARIANT guidelines, we provide the rare genetic disease community with guidance on how to identify suitable candidates for variant-specific ASO-based therapies and the possibility of integrating such assessments into routine clinical practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.958
Threshold uncertainty score0.953

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.076
GPT teacher head0.433
Teacher spread0.357 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designOther design
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations21
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueThe American Journal of Human GeneticsSame topicGenomics and Rare DiseasesFrench-language works237,207